Government faces pressure to overhaul Covid vaccine compensation scheme
The UK government has committed to reviewing the Vaccine Damage Payment Scheme after intense criticism from the Covid Inquiry and campaigners who say the system fails people who believe they were injured by vaccination or bereaved after a vaccine-related death. The issue sits at the intersection of vaccine safety, public trust, and state responsibility. Vaccination remains one of the most effective public health interventions ever deployed, and the AstraZeneca Covid jab is credited with saving millions of lives worldwide. Even so, a small number of people have experienced serious harm, and the compensation pathway built to support them has come under growing scrutiny.
More than 24,000 Covid-related claims have been submitted to the scheme, yet just over 1% have led to the one-off, tax-free payment of £120,000. Those figures sharpen the debate around whether a mechanism designed for rare injury can cope with the scale and complexity of claims linked to a mass vaccination programme. The current threshold requires applicants to show they are at least 60% disabled, a standard that can be difficult to satisfy in vaccine injury cases where impairment may be real, severe, and functionally devastating without fitting neatly into a rigid disability framework. In practical terms, the rule filters out many claimants before their cases reach a meaningful assessment of causation and impact.
One sentence captures the problem bluntly: the scheme is expensive, slow, and narrowly constructed.
The 60% disability threshold sits at the center of the dispute
Baroness Hallett, chair of the Covid Inquiry, called for urgent reform in her fourth report and said the scheme is not sufficiently supportive. Her criticism focused not on the existence of compensation itself, but on the design of a process that appears poorly matched to the reality of Covid vaccine claims. A fixed disability threshold can work awkwardly when injuries present with varied neurological, vascular, or systemic consequences and when the burden of proof falls on people already living with major health setbacks. For families trying to secure support, the issue is not abstract policy architecture; it is whether the system can recognize harm in a timely and humane way.
The government’s response says it is committed to reviewing the scheme so it is fit for purpose and delivered effectively. Ministers in England say they will work closely with the other nations of the UK and with people injured by the Covid vaccine and their families. That wording signals intent, but it stops short of a timetable, a redesign blueprint, or any guarantee that the disability threshold will change. Campaigners have seized on that gap. Vaccine Injured and Bereaved UK welcomed the recognition that vaccine injury and bereavement are real, yet said acknowledgement is not the same as action.
Campaigners are pressing for more than a promise to review
The group’s complaint is procedural and deeply personal. After more than five years of campaigning, and after the inquiry explicitly urged reform, families want a concrete commitment rather than another review layered on top of earlier reviews. They say there is a difference between saying the government will look further at the problem and saying it will deliver reform. Without a timetable, the current system continues to define the pace of compensation, medical assessment, and closure for claimants who believe the vaccine left them disabled or bereaved.
For public health authorities, these cases have a second-order consequence. A compensation program that appears inaccessible can erode confidence even in vaccination programs with clear population-level benefit. A fair system does not imply that vaccines are unsafe; it acknowledges that rare serious harms require an ethical response from the state. When that response is perceived as slow or opaque, mistrust can spread beyond the small group directly affected and into the wider conversation about immunization.
The administration costs sharpen that concern.
Administration costs now exceed direct payouts
The government has also acknowledged worries about the running costs of the scheme. Since April 2022, the VDPS has cost £83 million to run, a figure that includes administration and medical assessments. During the same period, £32 million has been paid out in financial support to victims. The imbalance is striking and raises immediate questions about efficiency, triage, and whether the scheme’s structure is absorbing too much money before it reaches claimants. When administrative spending outpaces compensation by such a margin, the process itself becomes part of the controversy.
There is a basic policy tension here. A compensation system must be rigorous enough to guard against fraudulent or unsupported claims, yet accessible enough to help the people it was created to serve. Overly burdensome assessment can protect the public purse while leaving legitimate claimants in limbo. A looser system may speed relief but invite disputes over causation and entitlement. The current debate suggests the balance has tilted too far toward process and too little toward support.
For those who believe they were harmed, the value of the payment is only one part of the story. The larger issue is recognition. A scheme that is too difficult to navigate can communicate disbelief, even when no such intent exists. In vaccine policy, where confidence depends on trust as much as on data, that symbolism matters.
A test of whether compensation can match mass vaccination policy
The Covid vaccine rollout saved lives on a scale few other interventions have matched. The compensation question does not change that fact. Instead, it asks whether a state that urges mass participation in a public health campaign is prepared to support the very small number of people who experience serious harm. The inquiry has now forced that question into the open, and the government has said it will review the scheme. What remains unresolved is whether review will produce a lower disability threshold, faster decisions, less administrative drag, or a redesigned pathway altogether.
Until those details are set out, claimants remain in a system that has been criticized for being insufficiently supportive and financially inefficient. The next stage will depend on whether ministers move from review language to structural reform, and whether the compensation model can be rebuilt in a way that is credible both to injured families and to the wider public health system.